Innocare Pharma Sustainability Profile
Innocare Pharma, a leading biopharmaceutical company headquartered in China (CN), is dedicated to advancing innovative therapies in the oncology and autoimmune disease sectors. Founded in 2015, the company has rapidly established itself as a key player in the industry, focusing on the development of novel treatments that address unmet medical needs. With a robust pipeline of targeted therapies and monoclonal antibodies, Innocare Pharma distinguishes itself through its commitment to research and development, leveraging cutting-edge technology to enhance patient outcomes. The company has achieved significant milestones, including successful clinical trials and strategic partnerships, solidifying its position in the global market. As Innocare Pharma continues to expand its operational reach, it remains focused on delivering high-quality, effective solutions that improve the lives of patients worldwide.
DitchCarbon Score
How does Innocare Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Innocare Pharma's score of 24 is lower than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Innocare Pharma's reported carbon emissions
Innocare Pharma, headquartered in China, reported total carbon emissions of approximately 12,134,540 kg CO2e for the year 2023. This figure includes 19,950 kg CO2e from Scope 1 emissions and a significant 12,114,590 kg CO2e from Scope 2 emissions. In comparison, the company’s total emissions for 2022 were about 9,835,800 kg CO2e, all attributed to Scope 2, as there were no Scope 1 emissions recorded that year. The trend shows an increase in total emissions from 9,236,400 kg CO2e in 2021, which also consisted solely of Scope 2 emissions. Innocare Pharma has not set specific reduction targets or initiatives as part of its climate commitments, nor does it report any emissions data for Scope 3. The absence of reduction targets suggests a need for further development in their sustainability strategy. The company’s emissions data is not cascaded from any parent organization, indicating that these figures are independently reported by InnoCare Pharma Limited. Overall, while Innocare Pharma has made strides in transparency regarding its emissions, the lack of defined reduction goals highlights an area for potential improvement in its climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | - | - | - | 00,000 |
| Scope 2 | 2,476,590 | 0,000,000 | 0,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
How Carbon Intensive is Innocare Pharma's Industry?
How Carbon Intensive is Innocare Pharma's Location?
Innocare Pharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Innocare Pharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
